Cargando…

Geographic and outcome variation among black men diagnosed with prostate cancer

BACKGROUND: Prostate cancer is the sixth leading cause of death from cancer among men worldwide. We have previously reported that prostate cancer survival rates for Caribbean-born males in the US was similar to survival rates of African-Americans and was higher than their counterparts diagnosed in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragin, Camille, Mutetwa, Batsirai, Attong-Rogers, Alison, Roach, Veronica, Taioli, Emanuela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194181/
https://www.ncbi.nlm.nih.gov/pubmed/21992682
http://dx.doi.org/10.1186/1750-9378-6-S2-S2
_version_ 1782213924759797760
author Ragin, Camille
Mutetwa, Batsirai
Attong-Rogers, Alison
Roach, Veronica
Taioli, Emanuela
author_facet Ragin, Camille
Mutetwa, Batsirai
Attong-Rogers, Alison
Roach, Veronica
Taioli, Emanuela
author_sort Ragin, Camille
collection PubMed
description BACKGROUND: Prostate cancer is the sixth leading cause of death from cancer among men worldwide. We have previously reported that prostate cancer survival rates for Caribbean-born males in the US was similar to survival rates of African-Americans and was higher than their counterparts diagnosed in the Caribbean. However, it is not clear whether differences in mortality could be attributed to differences in treatment. METHODS: This current analysis seeks to further explore reasons for the geographic variation of prostate cancer survival for Caribbean-born men. This analysis included 2,554 Black newly diagnosed prostate cancer cases (960 cases diagnosed in the US and 1,594 cases diagnosed in the Caribbean). Clinical data were extracted from the cancer registry and clinical charts. RESULTS: There were noted differences in the pattern of treatment for each place of birth category when stratified according to disease stage at diagnosis. Among the patients diagnosed with early-intermediate disease (stage I-III) the majority of US-born Brooklyn men were treated with surgery only (31%) and a similar pattern was observed for Caribbean-born Brooklyn men (35%). In contrast, the majority of Caribbean-born Trinidad & Tobago men were treated with hormone therapy (31%). Caribbean-born men diagnosed in the Caribbean had a significantly higher risk of death from prostate cancer (Adjusted Hazard [AdjHR]: 3.7, 95% Confidence Interval [CI]: 2.8-5.0) when compared with the risk of death for Caribbean-born males diagnosed in the US. This observation was consistent for each treatment group with the exception of the cases treated with hormone therapy only. For these cases, there was no difference in the risk of death between Caribbean-born males diagnosed in the Caribbean (AdjHR: 1.4, 95% CI: 0.8-2.6) compared to Caribbean-born males diagnosed in the US. CONCLUSIONS: In addition to difference in access and utilization of screening, differences in treatment strategy may also be a strong predictor of outcome for Caribbean-born males diagnosed with prostate cancer. Further studies are needed to confirm these findings. In addition, other environmental factors related to survival that was not considered in this analysis also need to be investigated.
format Online
Article
Text
id pubmed-3194181
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-31941812011-10-17 Geographic and outcome variation among black men diagnosed with prostate cancer Ragin, Camille Mutetwa, Batsirai Attong-Rogers, Alison Roach, Veronica Taioli, Emanuela Infect Agent Cancer Proceedings BACKGROUND: Prostate cancer is the sixth leading cause of death from cancer among men worldwide. We have previously reported that prostate cancer survival rates for Caribbean-born males in the US was similar to survival rates of African-Americans and was higher than their counterparts diagnosed in the Caribbean. However, it is not clear whether differences in mortality could be attributed to differences in treatment. METHODS: This current analysis seeks to further explore reasons for the geographic variation of prostate cancer survival for Caribbean-born men. This analysis included 2,554 Black newly diagnosed prostate cancer cases (960 cases diagnosed in the US and 1,594 cases diagnosed in the Caribbean). Clinical data were extracted from the cancer registry and clinical charts. RESULTS: There were noted differences in the pattern of treatment for each place of birth category when stratified according to disease stage at diagnosis. Among the patients diagnosed with early-intermediate disease (stage I-III) the majority of US-born Brooklyn men were treated with surgery only (31%) and a similar pattern was observed for Caribbean-born Brooklyn men (35%). In contrast, the majority of Caribbean-born Trinidad & Tobago men were treated with hormone therapy (31%). Caribbean-born men diagnosed in the Caribbean had a significantly higher risk of death from prostate cancer (Adjusted Hazard [AdjHR]: 3.7, 95% Confidence Interval [CI]: 2.8-5.0) when compared with the risk of death for Caribbean-born males diagnosed in the US. This observation was consistent for each treatment group with the exception of the cases treated with hormone therapy only. For these cases, there was no difference in the risk of death between Caribbean-born males diagnosed in the Caribbean (AdjHR: 1.4, 95% CI: 0.8-2.6) compared to Caribbean-born males diagnosed in the US. CONCLUSIONS: In addition to difference in access and utilization of screening, differences in treatment strategy may also be a strong predictor of outcome for Caribbean-born males diagnosed with prostate cancer. Further studies are needed to confirm these findings. In addition, other environmental factors related to survival that was not considered in this analysis also need to be investigated. BioMed Central 2011-09-23 /pmc/articles/PMC3194181/ /pubmed/21992682 http://dx.doi.org/10.1186/1750-9378-6-S2-S2 Text en Copyright ©2011 Ragin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Proceedings
Ragin, Camille
Mutetwa, Batsirai
Attong-Rogers, Alison
Roach, Veronica
Taioli, Emanuela
Geographic and outcome variation among black men diagnosed with prostate cancer
title Geographic and outcome variation among black men diagnosed with prostate cancer
title_full Geographic and outcome variation among black men diagnosed with prostate cancer
title_fullStr Geographic and outcome variation among black men diagnosed with prostate cancer
title_full_unstemmed Geographic and outcome variation among black men diagnosed with prostate cancer
title_short Geographic and outcome variation among black men diagnosed with prostate cancer
title_sort geographic and outcome variation among black men diagnosed with prostate cancer
topic Proceedings
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194181/
https://www.ncbi.nlm.nih.gov/pubmed/21992682
http://dx.doi.org/10.1186/1750-9378-6-S2-S2
work_keys_str_mv AT ragincamille geographicandoutcomevariationamongblackmendiagnosedwithprostatecancer
AT mutetwabatsirai geographicandoutcomevariationamongblackmendiagnosedwithprostatecancer
AT attongrogersalison geographicandoutcomevariationamongblackmendiagnosedwithprostatecancer
AT roachveronica geographicandoutcomevariationamongblackmendiagnosedwithprostatecancer
AT taioliemanuela geographicandoutcomevariationamongblackmendiagnosedwithprostatecancer